Content Library Home
Educational Content
My Account
Search
NACFC Home
Contact Us
Log-in / Create Account
The 21st Annual North American CF Conference
Session List
Click
here
to search this conference.
Display sessions grouped by:
Track
Session Code
Speaker
Date
Track:
Complete Conference Online Access / CM-ROM Set - Days 1-3 (Digital Audio with synchronized PowerPoint)
Special Educational Online Access / CD-ROM - SHORT COURSES (Digital Audio with synchronized PowerPoint)
Special Online Access / CD-ROMs by Day (Digital Audio with synchronized PowerPoint)
Complete Conference Online Access / CM-ROM Set - Days 1-3 (Digital Audio with synchronized PowerPoint)
SET Complete Conference CD-ROM Set - Days 1-3
Back to Top
Special Educational Online Access / CD-ROM - SHORT COURSES (Digital Audio with synchronized PowerPoint)
SCON Special Educational CD-ROM (Wednesday, October 3, 2007) - 9 SHORT COURSES
Back to Top
Special Online Access / CD-ROMs by Day (Digital Audio with synchronized PowerPoint)
DY1 Day 1 - Thursday, October 4, 2007
DY2 Day 2 - Friday, October 5, 2007
DY3 Day 3 - Saturday, October 6, 2007
P1 From Basic Science to the Clinic: Where Are We & What Is Still Missing
P1-0 Welcome & Introductions
P1-1 Plenary Session I: "From Basic Science to the Clinic: Where Are We & What Is Still Missing?"
S1 CFTR Structure: Putting It All Together
S1-0 Introduction
S1-1 CFTR Structure: What We Can Learn from Electron Microscopy
Structure of the Human CFTR NBD1 Domain as a Homodimer: Insights and Applications
S1-3 Novel Approaches for Expression, Stabilization and Crystallization of CFTR
S1-4 Modeling Full Length CFTR: From Sequence to Structure
Is It All Genetics?
Introduction
Non-genetic Influences on CF Disease Severity
Air Pollution As a Modifier of Lung Function
Gene-environment Interactions in Susceptibility to Tuberculosis Disease
Interactions Among Environmental and Genetic Factors that Affect CF Lung Disease Severity
Physics of Mucus Transport
Introduction
Rheology and Optimization of Adhesive Locomotion
Computational Model of Mucociliary Clearance - Relevance to Therapy
Polymer Physics of the Periciliary Layer
Mucociliary Clearance: Physics to Physiology
Pros and Cons: Gastrostomy Tubes in Patients with CF and Acid Suppression Improves PERT Function
Introduction
We Do Not Need to Use Gastrostomy Tubes (GT) to Improve Outcomes in Patients with CF
We Need to Use Gastrostomy Tubes to Improve Outcomes in Patients with CF
Acid Suppression Improves Effectiveness of Pancreatic Enzyme Replacement Therapy
Use of Acid Suppressive Agents Should Not be a Standard Part of CF Care
Identification of Novel Therapeutic Targets in the Post-genomic Era
Introduction
The Response of Bronchial Epithelial Cells to Pseudomonas aeruginosa: Beyond Gene Expression Profiling
Therapeutic Targets Defined by Pseudomonas aeruginosa Adaptation to the CF Airway
S5-3 Are Pulmonary Phospholipids and Fatty Acids Attractants or Foods for Pseudomonas aeruginosa?
Neuraminidase Inhibitors to Prevent P. aeruginosa Infection
Pain Management in the Cystic Fibrosis Patient
Introduction
Pain Management in the Cystic Fibrosis Patient: The Spectrum of Pain in the Hospitalized Patient with CF
Case Studies Panel Discussion
A Developmental Approach to Adolescent Pain
Controversial Issues in Aerosol Therapy
Introduction
Introduction to Aerosol Science
The Combination of Drug & Device Used for Respiratory Medications Should Be FDA Approved: Pro
The Combination of Drug & Device Used for Respiratory Medications Should Be FDA Approved: Con
Cleaning Controversies
W1 Modifier Genes
W10 Making the CF Diagnosis
W1-0 Introduction
W10-0 Introduction
W10-1 Use and Interpretation of CFTR Mutation Analysis in the Clinical Setting: An International Consensus
W10-2 CF Foundation Consensus on CF Diagnosis
W10-3 Redefining the Diagnostic Parameters for Cystic Fibrosis
W10-4 Abstract 185. The Reference Range for Sweat Chloride Testing and Genotype Analysis for Newborns Who Are Heterozygote Carriers of Cystic Fibrosis
W10-5 Abstract 187. CFTR Screening Does Not Identify All CFTR Coding Region Mutations in CF Patients
W10-6 Abstract 188. Diagnosing Cystic Fibrosis in Adults: Is Sweat Testing Still the Gold Standard?
W10-7 Discussion & Wrap-up
W1-1 Abstract 179. Variants in the Endothelin Receptor A Gene Associate with Increased Expression Levels, Increased Cell Proliferation, and More Severe Pulmonary Disease in CF Females
W1-2 Abstract 180. The Beta-Defensin Repeat Region Affects Cystic Fibrosis Lung Disease Severity
W1-3 Abstract 181. A 6 Megabase Region on the Long Arm of Chromosome 5 Displays Linkage to Cross-sectional and Longitudinal Measures of Cystic Fibrosis Lung Disease Severity
W1-4 Abstract 182. TCF7L2, a Risk Gene for Type 2 Diabetes, Is Associated with Cystic Fibrosis-related Diabetes
W1-5 Abstract 183. Assessing Mucin Gene Polymorphisms to Determine Their Role As Modifiers of Different CF Phenotypes
W1-6 Abstract 184. Assessment of Genetic Modifiers for Phenotypic Severity of Beta-ENaC Transgenic Mice
W1-7 Discussion & Wrap-up
W2 CFTR 2007
W2-1 Abstract 1. Processing and Function of CFTR-Î"F508 Are Species Dependent
W2-2 Abstract 2. Differences in Interactions of WT and Î"F508 NBD1 with Other Regions of CFTR
W2-3 Abstract 3. SHSPS Target Î"F508 CFTR for ERAD via the Sumo Pathway
W2-4 Abstract 4. Dynasore Prevents CFTR Removal From the Cell Surface
W2-5 Abstract 5. Identification of a Non-native State of NBD1 that Is Affected by Î"F508
W2-6 Abstract 6. CAL-dependent Degradation of CFTR by Trans-golgi Network Localized Snare Protein Syntaxin-6
W2-7 Discussion & Wrap-up
W3 Pushing the Envelope: New Concepts in CF Therapy
W3-0 Introduction
W3-1 Abstract 239. Repeated Administration of Lentiviral Vector to Mouse Nasal Epithelia Enhances Expression without Emergence of Blocking Mucosal Immune Responses
W3-2 Abstract 240. Bronchoscope-guided, Targeted Lobar Aerosolization of HDAD into Nonhuman Primate Lungs Results in Uniform, High Level Pulmonary Transduction, Long Term Transgene Expression and Negligible Toxicity
W3-3 Abstract 241. Airway Stem/Progenitor Cell Integration
W3-4 The Path to the Clinic for VX-770, a Novel CFTR Potentiator
W3-5 Abstract 242. High Throughput Screening Assay for Airway Mucin Secretion
W3-6 CF - HCO3- = Mucoviscidosis
W3-7 Discussion & Wrap-up
W4 CF Airway Defense and Redox State
W4-0 CF Airway Defense & Redox State: Introduction
W4-1 Abstract 143. Regulation of the LPO Antibacterial System Through Hydrogen Peroxide Production
W4-2 DUOX1 in the Airway Epithelium: Role in Epithelial Repair and Remodeling
W4-3 Abstract 144. Neutrophil Defects in Cystic Fibrosis
W4-4 Abstract 146. Dual Effects of Pyocyanin-induced Oxidative Stress on CFTR Chloride Transport
W4-5 Abstract 147. A Role of Glutathione Transport in the Attenuation of Oxidative Injury by Hypertonic Saline
W4-6 NO Plus
W4-7 Discussion & Wrap-up
W5 Infectious Diseases Management
W5-0 Introduction
W5-1 Abstract 305. Bacterial Microfloral Diversity of the Cystic Fibrosis Lung by 16S Ribosomal RNA
W5-2 Abstract 306. Antibiotic Susceptibility of Anaerobic Bacteria Cultured from the Sputum of Cystic Fibrosis Patients Grown Planktonically and as Biofilms
W5-3 Abstract 307. "Time to Event" Analysis of Efficacy of an Early Aggressive Eradication Protocol for First Growth Pseudomonas aeruginosa in Cystic Fibrosis
W5-4 Abstract 308. Phase 3 Trial (AIR-CF 1) Measuring Improvement in Respiratory Symptoms in Patients with Cystic Fibrosis Following Treatment with Aztreonam Lysine for Inhalation (AZLI)
W5-5 Abstract 309. A Comparison of Oral Chloramphenicol and Oral Ciprofloxacin in the Treatment of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis
W5-6 Abstract 310. Sustained Effect of Prophylactic Treatment with IgY Against P. aeruginosa Infections
W5-7 Discussion & Wrap-up
W6 Adult Issues in CF
W6-0 Introduction
W6-1 Testosterone Replacement in Males with CF
W6-2 Abstract 544. Self-reported Treatment Burden in Adults with Cystic Fibrosis
W6-3 Abstract 545. The Estimated Incidence of Patients with Cystic Fibrosis Having a CF Affected Child: A Survey of Centers Throughout the United States
W6-4 Abstract 546. Why Do So Few Men with Cystic Fibrosis Seek Fertility Treatment?
W6-5 Abstract 547. Cardiac Dysfunction in Adult CF Patients with Severe Lung Disease - A Retrospective CoHort Study
W6-6 CF Transition Care...an Adult Issue Also?
W6-7 Discussion & Wrap-up
W7 Medical & Psychosocial Challenges & Solutions to G-tube Placement Throughout the Lifecycle
W7-0 Introduction
W7-1 Abstract 484. Impact of Improved Nutritional Status with Gastrostomy Feedings on Pulmonary Exacerbations in Cystic Fibrosis
W7-2 Diagnosis & Dialogue: The Role of the Physician in the Tube Feeding Decision
W7-3 Family Centered Approach to the Initiation of Gastrostomy Tube Feedings
W7-4 Abstract 485. Percutaneous Endoscopic Gastrostomy (PEG) In Cystic Fibrosis: Effects on Nutrition and Pulmonary Function
W7-5 Challenges to Gastrostomy Tube Placement in Adolescent with Cystic Fibrosis
W7-6 Adults with Advanced Lung Disease and Gastrostomy Tube Placement
W7-7 Discussion & Wrap-up
W8 Assessment and Treatment of Depression in Pediatric and Adult Patients with CF
W8-0 Introduction
W8-1 Abstract 548. Emotional Distress in Parents of Infants with CFTR-related Disorders Diagnosed Through Neonatal Screening
W8-2 Preliminary Results of the National Depression and Anxiety Screening Study in Two CF Centers in Ohio
W8-3 Evidence-based Treatment for Adolescents with Depression
W8-4 Abstract 549. Physical Health and Anxiety Symptoms: Does Monitoring Mediate the Relationship?
W8-5 Comorbidity of Depression and Cystic Fibrosis in Children and Adolescents: Associations with Medical Adherence
W8-6 Levels of Depression and Anxiety in Hispanic Patients with CF and Their Caregivers
W8-7 Discussion & Wrap-up
W9 Time for Airway Clearance
W9-0 Introduction
W9-1 Exercise and Airway Clearance
W9-2 Abstract 431. Measuring Patient Compliance in Inhalation Studies by Smart Card Technology
W9-3 Strategies to Reduce Time for Airway Clearance
W9-4 Abstract 432. Delivery of Hypertonic Saline from an Adaptive Aerosol Delivery Nebulizer and a Conventional Jet Nebulizer
W9-5 Abstract 434. Aerosolization of Liposomal Amikacin (ArikaceTM) Using Different Nebulizers: Selection of the eFlow
W9-6 Abstract 435. Methodologies for Targeting Aerosolized Drugs to the Conducting Airways
W9-7 Discussion & Wrap-up
P2 CF Drug Development: What's New?
P2-0 Plenary Session II: "CF Drug Development: What's New?"
S10 Mucosal Pathogen Interaction
S10-0 Introduction
S10-1 Mucin Structure and Its Function As the Main Trap for Microbes
S10-2 Small Intestinal Bacterial Overgrowth in the CF Mouse: Roles of Mucus and Motility
S10-3 Microbial Community Assembly and Host-microbial Interactions in the Intestine
S10-4 When Pathogen Meets Host-Clues for Development of Novel Therapeutics
S11 Airway Defenses : New Developments in Host-Pathogen Interactions
S11-0 Introduction
S11-1 Hit Them Where They Eat: Antimicrobial Strategies that Target Bacterial Metabolism
S11-2 Polymicrobial Interactions in CF: Synergies and Antagonisms in Host Response
S11-3 Role of CFTR in the Regulation of Intracellular Acidification and Bacterial Killing in Alveolar Macrophages
S11-4 An Oxidant Driven Microbicidal System in Airway Epithelia
S12 Medical, Neurocognitive, and Psychosocial Effects of Sleep Problems in CF
S12-0 Introduction
S12-1 An Overview of Sleep in the CF Literature
S12-2 Sleep Disturbance and Pulmonary Function in CF Patients
S12-3 Sleep in CF - Is It Broken?
S12-4 Sleep Disordered Breathing in CF and Effects of Treatment
S13 Pulmonary and Nutritional Care of the Young Child with CF
S13-0 Introduction
S13-1 Nutritional Issues in Diagnosis and Management of Infants and Young Children with CF
S13-2 Breathing Lessons: How Can We Keep the Pre-school Lung Healthy?
S13-3 Using Diagnostic Tools in the Young Child: X-rays and Pulmonary Function Tests
S13-4 Guiding Parents on the CF Journey
S14 Update on Quality Improvement and Benchmarking
S14-0 Introduction
S14-1 The Adult CF Benchmarking Project: What Have We Learned?
S14-2 CF Quality Improvement: Effect on Outcomes
S14-3 Improving CF Outcomes at Children's Memorial Hospital: A Case Study
S14-4 The CF Foundation Quality Improvement Initiative: Lessons Learned and Future Directions
S8 CFTR: Biogenesis and Post-ER Quality Control
S8-0 Introduction
S8-1 Cotranslational Folding of Ribosome-bound Nascent CFTR Polypeptides
S8-2 Reconstitution and the Identification of New Factors Required for CFTR/Ste6p* Quality Control in the Endoplasmic Reticulum
S8-3 Membrane/Cytoplasmic Domain Contacts in CFTR
S8-4 ESCRTs in Membrane Trafficking and Quality Control
S9 CF Liver Disease: From the Bench to the Bedside
S9-0 Introduction
S9-1 Pathophysiology of CF-associated Liver Disease: Lessons from the Bench
S9-2 Biomarkers and Non-invasive Imaging for CF associated Liver Disease: Search for the Holy Grail
S9-3 Natural History of CF-associated Liver Disease
S9-4 Treatment Options for CF-associated Liver Disease
W11 Pulmonary Guidelines & Care
W11-0 Introduction
W11-1 Abstract 368. Large U.S. Cohort of Young Pseudomonas-negative CF Patients: Mild Lung Disease, Heterogeneous Management
W11-2 Abstract 369. Lung Function Is Diminished in Infants with CF Diagnosed by Newborn Screening Regardless of Pulmonary Infection Detected in Broncho-alveolar Lavage
W11-3 Abstract 370. Comparison of Antibiotics for Early Pseudomonas Infection in CF: Interim Data Analysis
W11-4 Abstract 371. Improvements in Lung Function and Nutritional Outcomes in Cystic Fibrosis
W11-5 Abstract 372. Effect of Key Phamacological Therapies on Decline in Lung Function in Adults with Cystic Fibrosis
W11-6 Abstract 373. Evaluation of a Pulmonary Exacerbation Score in Adults with Cystic Fibrosis
W11-7 Discussion & Wrap-up
W12 CFTR Structure & Protein Interactions
W12-0 Introduction
W12-1 Abstract 7. PKC Phosphorylation Is Necessary for PKA-dependent Binding of the Domain with the Rest of CFTR
W12-2 Abstract 8. Cooperative Domain Assembly Is Essential for CFTR Folding in Living Cells
W12-2B Abstract 10. Interactions with Nascent CFTR as it Exits the Ribosome
W12-3 Relationships Between CFTR Domain Folding and Chloride Channel Activation
W12-4 Abstract 11. ATP Occlusion at the First Nucleotide Binding Domain (NBD1) of CFTR Is Independent of the Second (NBD2) and Therefore of NBD Dimerization
W12-5 Abstract 12. CFTR Structure: What Can We Learn from Electron Microscopy?
W12-6 Discussion & Wrap-up
W13 Biomarkers of Airway Physiology & Host Defense
W13-0 Introduction
W13-1 Abstract 80. Standardization of Mucociliary and Cough Clearance Methodology
W13-2 Abstract 81. Assessment of Induced Sputum as a Tool to Evaluate Anti-inflammatory Agents in CF
W13-3 Abstract 82. UK CF Gene Therapy Consortium Tracking Study: Change in Sputum Properties in Response to IV Antibiotic
W13-4 Abstract 83. A Novel Proteolytically-derived Neutrophil Chemoattractant in Cystic Fibrosis: Role as Biomarker and Possible Therapeutic Target
W13-5 Abstract 84. Novel Mediators of Persistent Neutrophilic Inflammation in Cystic Fibrosis
W13-6 Abstract 85. A Simple and Non-invasive Method to Assess CF Airways Inflammation: Mass Spectrometric Detection of Purines and Urea in Exhaled Breath Condensate
W13-7 Discussion & Wrap-up
W14 Ion Transport & Mucosal Function
W14-0 Introduction
W14-1 Abstract 86. Chloride-bicarbonate Exchange in Human Bronchial Epithelial (HBE) Cells Treated with Interleukin 17A (IL-17A)
W14-2 Abstract 87. Activation of Nasal Epithelial CLC-2 Channels Rescues Chloride Transport in Cystic Fibrosis Mice
W14-3 Abstract 88. Adenosine-mediated Regulation of CFTR and ASL Homeostasis Requires an Intact Cytoskeleton
W14-4 Abstract 89. Dynamics of Liquid Secretion Responses of Porcine Tracheal Submucosal Glands to Acetylcholine and VIP
W14-5 Abstract 92. Protease Inhibitor Regulation of ENaC Function in the Airway: From in vitro to in vivo
W14-6 Abstract 93. Serca Pump Inhibitors Reduce Amiloride-sensitive Sodium Absorption and ENaC Expression
W14-7 Discussion & Wrap-up
W15 Microbial Diversity & Ecology of CF Airways
W15-0 Introduction
W15-1 Abstract 311. Detection of Anaerobic Bacteria in Sputum from Cystic Fibrosis Patients with an Acute Pulmonary Exacerbation
W15-2 Abstract 312. Molecular Identification of Bacteria in the CF Airway
W15-3 Abstract 313. Microbial Community Analysis of CF Sputum Using the Novel 16S rRNA
W15-4 Analysis of the Lung Bacterial Communities Present in Patients at Two Cystic Fibrosis Centers in America and Britain
W15-5 Abstract 314. The P. aeruginosa Burden of the CF Lung - Uncovering the Black Box
W15-6 Abstract 315. PCR Diagnosis of Respiratory Viruses in Children with Cystic Fibrosis
W15-7 Discussion & Wrap-up
W16 Increasing Social Support & Information Exchange Among Patients & Families
W16-0 Introduction
W16-1 Abstract 550. Perceived Social Support for Caregivers of Children with Cystic Fibrosis
W16-2 What Do Parents of Children with CF Want and Need Regarding Emotional and Spiritual Support from Their Healthcare Teams?
W16-3 Abstract 551. Evaluation of a Community Youth Befriending Service for Young People with CF
W16-4 Thank You for Caring, But Don't Tell Me What to Do: Adolescent Perspectives on Social Support from Peers, Family, and Healthcare Teams
W16-5 Abstract 552. Young Adults without Family Support - How Can We Help?
W16-6 Abstract 553. A DVD Presentation - An Adult Cystic Fibrosis Couples Support Group: Reducing Isolation while Living with Life-threatening Illness
W16-7 Discussion & Wrap-up
W17 QI - Lessons Learned
W17-0 Introduction
W17-1 Abstract 463. Improving Evidenced Based Awareness and Practitioner Use of CF Pulmonary Medications
W17-2 Abstract 464. Optimizing Lung Function in People with Cystic Fibrosis Through Consistent and Aggressive Identification and Treatment of Pulmonary Exacerbations
W17-3 Abstract 465. The Impact of Re-education of Airway Clearance Techniques (REACT) on Adherence and Pulmonary Function in Patients with Cystic Fibrosis
W17-4 Abstract 466. Maintain the Gain: Application of Continuous Quality Improvement to Nutritional Cystic Fibrosis Care
W17-5 Abstract 467. Project 4 or More: Improving Clinic Attendance to Four or More Times a Year at Arkansas Children's Hospital Cystic Fibrosis Care Center
W17-6 Abstract 468. Evaluation of Northeastern Ontario's Clinic Round Table Format
W17-7 Discussion & Wrap-up
W18 Infection Control
W18-0 Introduction
W18-1 Abstract 317. Epidemiology of Anterior Nares Colonization with Staphylococcus aereus in Children with CF and Their Household Members
W18-2 Abstract 318. Implementation of an Eradication Protocol and Revision of Infection Control Guidelines to Reduce MRSA Rates in Pediatric Patients with Cystic Fibrosis
W18-3 Abstract 319. Effectiveness of Alcohol-based Cleansers During CF Clinic Visits in Reducing Patient Hand Contamination by Respiratory Pathogens
W18-4 A Practical Approach to Infection Control
W18-5 Barriers to Adherence to Infection Control as Experienced by Healthcare Professionals Compared with CF Patients and Their Families
W18-6 Infection Control or Social Control: The Psychosocial Impact on CF Patient and Their Families
W18-7 Discussion & Wrap-up
W19 GI, Liver, & Nutrition Research
W19-0 Introduction
W19-1 Abstract 486. Treatment with Ursodeoxycholic Acid, But Not with Cholic Acid Increases Bile Flow Independently of Cystic Fibrosis Transmembrane Regulator in Mice
W19-2 Abstract 487. Ursodeoxycholic Acid (UCDA) Therapy in a Congenic CF-Mouse Model of Liver Disease
W19-3 Abstract 488. Altered Eicosanoid Metabolism in the CF Mouse Small Intestine
W19-4 Abstract 489. Reproducibility of the Malabsorption Blood Test (MBT)
W19-5 Abstract 490. Immunomodulatory Properties of Vitamin D in Scandinavian Cystic Fibrosis Patients
W19-6 Abstract 491. Anemia Is a Serious Comorbid Condition in Cystic Fibrosis and Is Associated with Poor Lung Function
W19-7 Discussion & Wrap-up
W20 Multi-disciplinary Update on Lung Transplant: Pre & Post Care
W20-0 Introduction
W20-1 Nutritional Considerations Pre and Post Lung Transplant
W20-2 Abstract 420. CT Scans from CF Patients Screened for Lung Transplant: The Severe Advanced Lung Disease (SALD) CT Scoring System and Correlation with Survival: Preliminary Results
W20-3 Fit for Transplant: Physiotherapy Issues and Optimisation
W20-4 Abstract 421. A Prospective Randomized Trial Comparing Airway Clearance Strategies Following Lung Transplantation
W20-5 Abstract 423. Cystic Fibrosis Quality of Life Comparison Between Male vs. Female Pediatric Lung Transplant Recipients
W20-6 Abstract 424. Lack of Progression of Liver Disease in CF Patients Following Lung Transplantation - Evidence that Lung Transplantation Is Safe in this Group of Patients
W20-7 Discussion & Wrap-up
P3 Improving Patient Outcomes Using the Tools We Have Now
P3-0 Plenary Session III: "Improving Patient Outcomes Using the Tools We Have Now"
S15 Regulation of Airway Surface Liquid
S15-0 Introduction
S15-1 Aquaporins and Their Role in ASL Volume Homeostasis
S15-2 Regulation of Airway ENaCs by Proteases: An Increasingly Complex Story
S15-3 Control of CFTR-mediated ASL Secretion by Adenosine and ENaC
S15-4 Airway Surface Liquid pH and Innate Defense by the NADPH Oxidase
S16 Outcome Measures to Assess CF Interventions
S16-0 Introduction
S16-1 Invasive and Non-invasive Markers of Airway Inflammation
S16-2 Measures of CFTR Molecular and Clinical Function
S16-3 Lower Airway Markers of Infection and Inflammation
S16-4 Measures of Mucociliary Clearance in Assessment of New CF Therapies
S17 The Inflammatory Process in CF: A Complex Picture with Many Players
S17-0 Introduction
S17-1 Revisiting the Role of CFTR Deficiency in Promoting Inflammation
S17-2 Cytokines of the Innate and Adaptive Immune System in CF Lung Inflammation
S17-3 A Unifying Theory to Explain How CFTR Leads to the Lipid Abnormalities in CF and Altered Inflammatory Signaling
S17-4 A Real-life View of Inflammation in CF: Novel Functional Assays for Immune Cell Analysis
S18 Bone Disease: Pathophysiology & Measurements
S18-0 Introduction
S18-1 Pediatric Bone Health: Starting at the Beginning
S18-2 CF Bone Disease: Is Mutant CFTR Really the Culprit?
S18-3 The Value of High-dose Cholecalciferol Supplementation to Replenish Vitamin D in CF
S18-4 The Influence of Pulmonary Infection on Bone Metabolism in Cystic Fibrosis
S19 Clinical Infectious Diseases
S19-0 Introduction
S19-1 Impact of MRSA on Clinical Status in CF
S19-2 Current Antibiotic Resistance Patterns in CF
S19-3 New Antibiotic Strategies for Treating Pulmonary Infection with Pseudomonas aeruginosa
S19-4 The Challenge of Emerging Pathogens in CF
S20 Herding Cats: Coordinating CF Care Today
S20-0 Introduction
S20-1 Living with the Complicated CF Patient: A Parent's Perspective
S20-2 Juggling, Balancing and Other Circus Acts: Orchestrating Pediatric CF Care
S20-3 Coordinating of Care and the Pursuit of Infection Control
S20-4 Research Coordination: How Does it Fit Into the Big Picture?
W21 Newborn Screening & Genetics
W21-0 Introduction
W21-1 Abstract 189. An Improved Newborn Screening Algorithm in Colorado: IRT/IRT/DNA
W21-2 IRT/Mutation Panel/DNA Sequencing - the California Model for CF Newborn Screening
W21-3 Abstract 190. Development of a DNA-based Cystic Fibrosis Newborn Screening Proficiency Testing Program
W21-4 Borderline Sweat Tests in CF Newborn Screening - Diagnostic Dilemmas and Long Term Follow-up
W21-5 Abstract 191. Adolescents and Young Adults with CF: Knowledge of the Genetic Basis of CF and Their Reproductive Risks
W21-6 Abstract 192. Patient Assessment of Genetic Counseling and Cystic Fibrosis Newborn Screening Program at the University of Minnesota Medical Center, Fairview
W21-7 Discussion & Wrap-up
W22 Molecular Mechanisms for CFTR Correction & Potentiation
W22-0 Introduction
W22-1 Abstract 243. Correction of ?F508 CFTR Trafficking Defect by a Novel Family of Marine Sponge Derived Alkaloids
W22-2 Abstract 244. Rescuing ?F508-CFTR Retention with CFTR Derived Peptides Containing the Di-basic RXR Motif (CF-RXR)
W22-3 Abstract 245. Small Molecular Correctors Increase the Surface Stability of Rescued ?F508 CFTR
W22-4 Abstract 246. Design and Synthesis of a Hybrid Potentiator-corrector Agonist of ?F508-CFTR
W22-5 Abstract 247. N6-(2-Phenylethyl)-ATP Potentiates G551D-CFTR by Binding to the Hydrolysis-incompetent Site (NBD1)
W22-6 Abstract 248. VX-770, A Potent, Selective, and Orally Bioavailable Potentiator of CFTR Gating
W22-7 Discussion & Wrap-up
W23 Airways Epithelial Biology
W23-0 Introduction
W23-1 Abstract 94. Differential Expression of Sarcoendoplasmic Reticulum Calcium Atpases (Sercas) in Cystic Fibrosis (CF) Epithelium
W23-2 Abstract 95. Evaluation of the SCN-/H2O2/Lactoperoxidase System as an Antibacterial Defense in Human Airway Epithelium
W23-3 Abstract 96. Flagellin Activates P38, PI3 Kinase, NF-KB and CFTR-dependent Cl Secretion in Airway Gland Epithelial Cells
W23-4 Abstract 97. Hypertonic Challenge Inhibits Sodium Transport in Human Bronchial Epithelial Cells
W23-5 Abstract 98. The Soluble Protein Plunc Regulates ENaC in Human Bronchial Cell Cultures
W23-6 Abstract 99. Prostasin Expression Is Regulated by Airway Surface Liquid Volume and Is Increased in Cystic Fibrosis
W23-7 Discussion & Wrap-up
W24 National/International CF Registries & QI
W24-0 Introduction
W24-1 Public Reporting of Cystic Fibrosis Outcomes: Methods for Case-Mix Adjustment
W24-2 Abstract 447. A Patient and Family Survey to Collect the Socioeconomic Variables in the Cystic Fibrosis Foundation Patient Registry: Methods and Results
W24-3 Abstract 448. Trends in CF Respiratory Microbiology in the U.S., 1995-2005
W24-4 Abstract 449. Multi-slope Models of Lung Disease as an Alternative to Single Slope Models
W24-5 Abstract 450. Predictors of Hospitalization in Cystic Fibrosis: Is There a Gender Gap?
W24-6 European Registry
W24-7 Discussion & Wrap-up
W25 Interactions of Pathogens & the CF Host
W25-0 Introduction
W25-1 Abstract 320. Persistent Nontypeable Haemophilus influenzae Infection Induces Airway Epithelial Tolerance to Pseudomonas aeruginosa
W25-2 Abstract 321. Human Airway Epithelial Cells Facilitate Biofilm Formation by Pseudomonas aeruginosa
W25-3 Abstract 322. The Pseudomonas aeruginosa Biofilm Matrix: A Mannose- and Galactose-rich Exopolysaccharide Is Anchored in a Helical Pattern on the Cell Surface and Acts as an Extracellular Scaffold Holding Biofilm Cells Together
W25-4 Abstract 323. Pseudomonas aeruginosa Induces Rapid Necrotic Killing of PMNs by Quorum Sensing-controlled Production of Rhamnolipid
W25-5 Abstract 324. Pseudomonas aeruginosa in Cystic Fibrosis: Pyocyanin Negative Strains Are Associated with BPI-ANCA and Progressive Lung Disease
W25-6 Abstract 325. Pseudomonas aeruginosa Type III Secretion and Lung Function Decline in Cystic Fibrosis
W25-7 Discussion & Wrap-up
W26 Models of Palliative Care
W26-0 Introduction
W26-1 End of Life: The Importance of Family-centered Care
W26-2 Advance Directives: Interventions at Emory
W26-3 Abstract 554. Advance Care Planning in Adults with CF
W26-4 End of Life Discussion: Is There Still Hope
W26-5 Developing a Palliative Care Approach to CF
W26-6 Discussion & Wrap-up
W27 Patient-Family Centered Care
W27-0 Introduction
W27-1 Abstract 572. Improving Team Communication on the Inpatient Pulmonary Unit
W27-2 Teaching the Newly Diagnosed Adult: Using a Creative Approach
W27-3 Strengthening Partnerships by Engaging Families as Members of the CF Team
W27-4 Passport for Teens: Helping Families Facilitate Transition
W27-5 Teaching Day for Teens
W27-6 Discussion & Wrap-up
W28 Parenting Challenges & Parent Stress: Overcoming Barriers to Adherence to Treatments
W28-0 Introduction
W28-1 Abstract 555. Effects of Caregiver Depression on Self-reported and Electronically Monitored Enzyme Adherence and Short-term Changes in Weight for Children with CF
W28-2 Abstract 556. Challenges of Living with Cystic Fibrosis (CLCF): Psychometric Evaluation of a New Measure
W28-3 Abstract 557. Effects of Behavioral-family Systems Therapy on Family Conflict and Communication in Adolescents with CF and Their Parents
W28-4 Bridging the Gap Between Research and Application: Provider and Parent Perspectives
W28-5 Helping Families of Young Children Meet Care Goals: Case Presentations
W28-6 Helping the Families of School-age Children Meet Care Goals: Case Presentations
W28-7 Discussion & Wrap-up
W29 Fatty Acids & Inflammation: Alterations in Uptake & Metabolism of Fatty Acids in CF
W29-0 Introduction
W29-1 Introduction to Fatty Acid Metabolism
W29-2 Abstract 492. Increased Metabolism of Linoleic Acid Through the N-6 Pathway in Cultured Cells with a Cystic Fibrosis Phenotype Is Corrected by Docosahexaenoic Acid (DHA) Supplementation
W29-3 Abstract 494. Impaired PPAR? Regulation as a Key Player in CF Fatty Acid Imbalance
W29-4 Abstract 495. Decreased PEMT Activity in CF Mice Is Dependent on Cholin Status
W29-5 Abstract 496. Type of Dietary Fat Intake to Serum Fatty Acid Status in Children with CF
W29-6 Discussion & Wrap-up
W30 Physical Activity & Exercise in CF - What Are the Outcomes?
W30-0 Introduction
W30-1 Abstract 436. Effects of Different Conditioning Programs on Quality of Life in CF
W30-2 Abstract 437. Effects of an Exercise Program on Motor Performance in Preschool Children with CF
W30-3 Abstract 438. Motor Performance in Preschool Children with CF Compared to Healthy Children
W30-4 Abstract 439. Reliability and Validity of the Habitual Activity Estimation Scale (HAES) in Patients with Cystic Fibrosis
W30-5 Abstract 440. Long-term Effect of Habitual Physical Activity on Lung Health in Patients with Cystic Fibrosis
W30-6 Abstract 441. Development of an Exercise Knowledge Test for Children with Cystic Fibrosis
W30-7 Discussion & Wrap-up
SC1 Drug Treatment Options in CF Care: Beyond the Basics
SC1-0 Antimicrobial Therapy in Cystic Fibrosis - Beyond the Basics
SC1-1 Use of Antibiotics in Difficult to Manage CF Patients
SC1-2 Treatment and Prevention of early P. aeruginosa infection
SC1-3 MRSA Infection in Cystic Fibrosis
SC1-4 Optimizing Management of Pulmonary Exacerbation in Cystic Fibrosis
SC2 CF Basic Science for the Clinician
SC2-0 Introduction
SC2-1 CFTR: Gene to Protein - How Mutations in CFTR Lead to Cystic FibrosisA Basic Scientist's View
SC2-2 How does CFTR work as a chloride channel, and how do we study its function?
SC2-3 CF Lung Disease
SC2-4 Therapy for Cystic Fibrosis Based on a Rational Understanding of CFTR
SC3 Advanced Motivational Interviewing & CF: A Practical Workshop for Teams
SC3-0 Introductions
SC3-1 Adherence & the therapeutic relationship
SC3-10 The Next Step
SC3-2 Motivational Interviewing REFRESHER
SC3-3 Expressing empathy
SC3-4 Rolling With Resistance
SC3-5 Change & Supporting Self-Efficacy
SC3-6 MI in practice
SC3-7 Information Exchange
SC3-8 Non Diirective Skills
SC3-9 Signs of Resistance
SC4 Quality Improvement in CF Care: Steal Shamelessly, Share Generously
SC4-0 CF Strategic QI Initiative
SC4-1 Overview of Clinical Microsystems Thinking
SC4-2 Getting Started with the Fundamentals
SC4-3 Diagnosis, Improvement Ramp, Aims, FlowchartsCase
SC4-4 Change Concepts, PDSA-SDSA
SC4-5 Smart Change Ideas & Pulmonary Case
SC4-6 Nutrition Case
SC4-7 Engaging Patients and Families
SC4-8 Discussion and Wrap Up
SC5 Implementation of CF Newborn Screening & Current Approaches to Evaluation & Treatment
SC5-0 Introduction
SC5-1 Experience with the Rubric in Washington State
SC5-2 Experience with the Rubric: California
SC5-3 Experience with the Rubric: Challenges in Utah
SC5-4 Completing the communications circle for QA
SC5-5 Family focus after the initial diagnosis
SC5-6 Malnutrition: Prevention and Treatment
SC5-7 Lung Disease: Prevention and Treatment
SC5-8 SC5.8 TBD
SC6 Challenges & Goals for Clinical Research Practice Management
SC6-0 Introduction
SC6-1 The Why, What, and When of SOPs
SC6-2 Best Practices for Study Implementation
SC6-3 Tools for Efficiency
SC6-4 Leadership/Management Balance
SC7 Pulmonary Pathophysiology & Pharmacology for Advanced Practice Nurses
SC7-1 Cystic Fibrosis Lung Disease: pathophysiology, disease complications, and treatment
SC7-2 Pulmonary Function Testing in CF: Infant to Adult
SC7-3 Pulmonary Pharmacology in Cystic Fibrosis
SC7-4 Use & Interpretation of Different Radiology Techniques in Assessing Pulmonary Status in Patients with Cystic Fibrosis
SC7-5 Beyond the Physical - a Holistic Approach to Care
SC7-6 Questions
SC8 Basic ACT for the CF Team
SC8-0 Introduction
SC8-1 Active Cycle of Breathing
SC8-2 Autogenic Drainage
SC8-3 Positive Expiratory Pressure
SC8-4 Oscillating PEP
SC8-5 High Frequency Chest Wall Oscillation
SC8-6 Other Modalities
SC8-7 Review of Literature
SC8-8 Patient Selection
SC8-9 Conclusion
SC9 CF Nutrition 101
SC9-0 Nutrition for Cystic Fibrosis 101
SC9-1 Why is nutrition for CF different than nutrition for the general population?
SC9-2 Vitamins and Minerals
SC9-3 Nutrition in Bone Health in CF
SC9-4 Pancreatic Enzyme Replacement Therapy
SC9-5 Newly Diagnosed CF Patient
SC9-6 Nutrition Assessment - Tube Feedings
SC9-7 Nutrition Management of Cystic Fibrosis Related Diabetes (CFRD)
SC9-8 Nutrition and Port CF
SC9-9 Benchmarking Themes
Back to Top